Sarepta price target lowered to $183 from $202 at Needham
Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...
GlobalData on MSN19h
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...
AstraZeneca's metastatic breast cancer treatment gets EU nod
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ:AZN) said on Friday that Enhertu received European Union approval for the ...
Zacks Investment Research on MSN20h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the ...
Clinical Trials Arena18h
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect of the Aβ mAb drug class.
Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved
Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a ...